REGENXBIO Completes RGX-202 Trial Dosing, Sets Stage for 2027 Duchenne Approval
Event summary
- REGENXBIO completed dosing in the confirmatory study of RGX-202 for Duchenne muscular dystrophy, ahead of schedule due to strong patient demand.
- The company plans to submit a Biologics License Application (BLA) under the accelerated approval pathway in Q3 2026, targeting FDA approval in 2H 2027.
- RGX-202 met its primary endpoint with >93% of patients achieving 10% microdystrophin expression at Week 12 and showed a favorable safety profile.
- The BLA will include data from 63 patients in the AFFINITY DUCHENNE® study, with 12-month functional data for at least half of the pivotal cohort.
The big picture
REGENXBIO's completion of the RGX-202 confirmatory study marks a critical step toward addressing the unmet need in Duchenne muscular dystrophy, a severe and progressive condition affecting young boys. The company's strategic focus on leveraging the FDA's accelerated approval pathway reflects broader industry trends favoring expedited pathways for rare disease therapies. With a robust safety dataset and strong functional improvements observed in early data, REGENXBIO is positioning RGX-202 as a potential best-in-class gene therapy, potentially reshaping treatment options for Duchenne patients.
What we're watching
- Regulatory Pathway
- How the FDA's accelerated approval pathway will influence the timeline and conditions for RGX-202's potential approval.
- Commercial Readiness
- The pace at which REGENXBIO can scale manufacturing and prepare for commercial launch following a potential approval.
- Competitive Landscape
- Whether RGX-202's differentiated microdystrophin construct will position it as a leading therapy in the Duchenne market.
Related topics